Using telehealth to improve lung cancer screening decision-making
Integrating Telehealth to Advance Lung Cancer Screening
This study tests if using telehealth can help patients make better decisions about lung cancer screening and ensure everyone has equal access to this important care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 6000 (estimated) |
| Ages | 50 Years to 80 Years |
| Sex | All |
| Sponsor | Abramson Cancer Center at Penn Medicine Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT06638554 on ClinicalTrials.gov |
What this trial studies
This pragmatic trial aims to determine if telehealth strategies can enhance shared decision-making (SDM) for lung cancer screening among patients. It employs a Sequential Multiple Assignment Randomized Trial (SMART) design, which includes two stages of interventions: initial patient outreach to schedule telehealth or in-person SDM visits, followed by text message reminders or phone-based digital care coordination for non-responders. The study also evaluates the effectiveness of these strategies across different races and sexes to ensure equitable access to lung cancer screening.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 50 to 80 with a significant history of tobacco use and no prior lung cancer screening in the last 24 months.
Not a fit: Patients with a documented history of lung cancer or those who do not meet the inclusion criteria will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly increase the rates of lung cancer screening through improved patient engagement and decision-making.
How similar studies have performed: Other studies have shown promising results using telehealth strategies for improving patient engagement in healthcare, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: Participants will be eligible if: 1. are aged 50 to 80 2. have a history of tobacco use indicated by either: Documented 20 pack-year or greater smoking history in their electronic health record (EHR); OR Self-report via structured survey 3. currently smoke or formerly smoked cigarettes 4. have no documented history of lung cancer 5. have no documented history of lung cancer screening in the 24 months prior to study enrollment 6. have completed at least one primary care visit at Penn Medicine in the 3 years prior to study enrollment. Exclusion criteria: Participants who do not meet inclusion criteria will not be eligible.
Where this trial is running
Philadelphia, Pennsylvania
- University of Pennsylvania — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: Katharine Rendle, PhD — Abramson Cancer Center
- Study coordinator: Katharine Rendle, PhD
- Email: katharine.rendle@pennmedicine.upenn.edu
- Phone: 215-349-5442
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.